THERAPY DOSSIER · th-d7ba43213492

Omental adipose mesenchymal stromal cell-derived microvesicles (resting, anti-inflammatory and proinflammatory preparations)

Biologic · Biologic (adipose MSC-derived microvesicles/exosomes); not a ChEMBL entity, preclinical

Evidence & regulatory context

Mechanism: Biologic (adipose MSC-derived microvesicles/exosomes); not a ChEMBL entity, preclinical
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24662862 ↗2014Reported benefit

The mesenchymal stem cell-derived microvesicles enhance sciatic nerve regeneration in rat: a novel approach in peripheral nerve cell therapy.

RatOtherWistarMaleLocal application at the nerve repair siteAt the time of nerve transection and conduit placement

Model: Sciatic nerve transection with a 10 mm gap bridged by a chitosan conduit

Resting and anti-inflammatory mesenchymal stem cell-derived microvesicles produced marked improvement in functional, electrophysiological, muscle mass, histomorphometric and immunohistochemical indices of sciatic nerve regeneration compared with proinflammatory microvesicles.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…